Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 5, 2010, Pages 1128-1133

  Salimi Moosavi, Hossein ^a   Lee, Jean ^a   DeSilva, Binodh ^a   Doellgast, George ^a  

^a AMGEN INC   (United States)

Author keywords

Acid guanidine dissociation; Alkaline dissociation; Duplex immunoassay; Ligand binding assay; Therapeutic interference; Total target measurement

Indexed keywords

ALKALINE EARTH METAL; BUFFER; GUANIDINE; LIGAND; MONOCLONAL ANTIBODY; PROTEIN;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MEASUREMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; STANDARD;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; BINDING SITES, ANTIBODY; BLOOD PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUANIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; PROTEIN CONFORMATION; PROTEIN DENATURATION; REPRODUCIBILITY OF RESULTS;

EID: 72749084561     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.11.021     Document Type: Article

References (25)

1. Roopenian D.C., and Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (2007) 715-725
2. Mutsaers A.J., Francia G., Man S., Lee C.R., Ebos J.M.L., Wu Y., Witte L., Berry S., Moore M., and Kerbel R.S. Dose-dependent increases in circulating TGF-α and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin. Cancer Res. 15 (2009) 2397-2405
3. Lobo E.D., Hansen R.J., and Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93 (2004) 2645-2668
4. S. Tannebaum, A. Gautier, P. Lowe, A mechanism based binding model for the population pharmacokinetics and pharmacodynamics of canakinumab, a monoclonal antibody in development for rheumatoid arthritis, 2008 AAPS Annual Meeting. Atlanta, GA, www.aapsj.org/abstracts/AM_2008/AAPS2008-002581.PDF.
5. Hayashi N., Tsukamoto Y., Sallas W.M., and Lowe P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63 (2006) 548-561
6. Kelly M., and DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J. 9 (2007) E156-E163
7. Lee J., and Ma H. Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins. AAPS J. 9 (2007) E164-E170
8. Smolec J., DeSilva B., Smith W., Weiner R., Kelly M., Lee B., Khan M., Tracy R., Hill H., and Celniker A. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22 (2005) 1425-1431
9. Davis R.A., Butterfiled A.M., Konard R.J., and Bourdage J.S. A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker. J. Pharm. Biomed. Anal. 48 (2008) 897-901
10. Zav'yalov V.P., Troitsky G.V., Demchenko A.P., and Generalov I.V. Temperature and pH dependent changes of immunoglobulin G structure. Biochim. Biophys. Acta 386 (1975) 155-167
11. Kats M., Richberg P.C., and Hughes D.E. pH-dependent isoform transitions of a monoclonal antibody monitored by micellar electrokinetic capillary chromatography. Anal. Chem. 69 (1997) 338-343
12. Chung J., and Nishida T. Dissociation of low density lipoprotein-antibody precipitates at alkaline pH. J. Lipid Res. 8 (1967) 631-635
13. Vermeer A.W.P., and Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys. J. 78 (2000) 394-404
14. Hathout Y., Setlow B., Martinez R.-M.C., Fenselau C., and Setlow P. Small, acid-soluble proteins as biomarkers in mass spectrometry analysis of Bacillus spores. Appl. Environ. Microbiol. 69 (2003) 1100-1107
15. Cortese M.S., Baird J.P., Uversky V.N., and Dunker A.K. Uncovering the unfoldome: enriching cell extracts for unstructured proteins by acid treatment. J. Proteome Res. 4 (2005) 1610-1618
16. Doellgast G.J., Spiegel J., Guenther R.A., and Fishman W.H. Studies on human placental alkaline phosphatase purification by immunoabsorption and comparison of the "A" and "B" forms of the enzyme. Biochim. Biophys. Acta 484 (1977) 59-78
17. Johnson W.C., and Tipper D.J. Acid-soluble spore proteins of Bacillus subtilis. J. Bacteriol. 146 (1981) 972-982
18. Matsudomi N., Sasaki T., Kato A., and Kobayashi K. Conformational changes and functional properties of acid-modified soy protein. Agric. Biol. Chem. 49 (1985) 1251-1256
19. Mesiano S., Young I.R., Browne C.A., and Thorburn G.D. Failure of acid-ethanol treatment to prevent interference by binding proteins in radioligand assays for the insulin-like growth factors. J. Endocrinol. 119 (1988) 453-460
20. Patton A., Mullenix M.C., Swanson S.J., and Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 304 (2005) 189-195
21. Setlow P. Purification and characterization of additional low-molecular-weight basic proteins degraded during germination of Bacillus megaterium spores. J. Bacteriol. 136 (1978) 331-340
22. Spelsberg T.C., Mitchell W.M., and Chytil F. Structural alterations of acidic proteins by acid treatment of chromatin. Mol. Cell. Biochem. 1 (1973) 243-251
23. Bhuyan A.K. Protein stabilization by urea and guanidine hydrochloride. Biochemistry 41 (2002) 13386-13394
24. Torta F., Dyuysekina A.E., Cavazzini D., Fantuzzi A., Bychkova V.E., and Rossi G.L. Solvent-induced ligand dissociation and conformational states of cellular retinol-binding protein type I. Biochim. Biophys. Acta 1703 (2004) 21-29
25. Kawahara K., Kirshner A.G., and Tanford C. Dissociation of human CO-hemoglobin by urea, guanidine hydrochloride, and other reagents. Biochemistry 4 (1965) 1203-1213